Cervical cancer therapies: Current challenges and future perspectives

• Published in: Tumour virus research 2022-06, Vol.13, p.200238, Article 200238
• Main Authors: Burmeister, Carly A., Khan, Saif F., Schäfer, Georgia, Mbatani, Nomonde, Adams, Tracey, Moodley, Jennifer, Prince, Sharon
• Format: Article
• Language: English
• Subjects: Cervical cancer; Combination therapy; Female; HPV E6/E7 oncoproteins; HPV therapeutic Vaccines; Humans; Immune checkpoint inhibitors; Oncogene Proteins, Viral - genetics; Papillomaviridae - genetics; Papillomavirus E7 Proteins - genetics; Papillomavirus Infections - complications; Review; Targeted therapy; Uterine Cervical Neoplasms - therapy
• ISSN: 2666-6790; 2666-6790
• DOI: 10.1016/j.tvr.2022.200238

Cervical cancer is the fourth most common female cancer worldwide and results in over 300 000 deaths globally. The causative agent of cervical cancer is persistent infection with high-risk subtypes of the human papillomavirus and the E5, E6 and E7 viral oncoproteins cooperate with host factors to induce and maintain the malignant phenotype. Cervical cancer is a largely preventable disease and early-stage detection is associated with significantly improved survival rates. Indeed, in high-income countries with established vaccination and screening programs it is a rare disease. However, the disease is a killer for women in low- and middle-income countries who, due to limited resources, often present with advanced and untreatable disease. Treatment options include surgical interventions, chemotherapy and/or radiotherapy either alone or in combination. This review describes the initiation and progression of cervical cancer and discusses in depth the advantages and challenges faced by current cervical cancer therapies, followed by a discussion of promising and efficacious new therapies to treat cervical cancer including immunotherapies, targeted therapies, combination therapies, and genetic treatment approaches.